Tris Pharma is considering all options when it comes to commercializing the novel drug cebranopadol for acute pain after a second Phase III trial read out positively. The company is on track to file cebranopadol with the US Food and Drug Administration later this year and Tris said it is prepared to commercialize the drug independently if needed but is exploring all options.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?